Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to study the safety and immune response of people who
receive a personalized dendritic cell vaccine with the intention of stimulating the immune
system to react to lung cancer cells.